labetalol and Cardiovascular Diseases studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"The effect of labetalol on blood pressure, heart rate and the renin-angiotensin system was evaluated in 12 patients with severe essential hypertension (diastolic blood pressure greater than or equal to 120 mmHg, WHO: Phase I and II) who had been resistant to other therapeutic regimens."	7.66	Treatment of severe essential hypertension with labetalol: effect on active and inactive renin. ( Hauger-Klevene, JH, 1981)
"Labetalol, a drug with alpha- and beta-adrenergic receptor blocking effects, was used to attenuate hypertension and tachycardia associated with electroconvulsive therapy (ECT) in a series of 11 elderly patients with refractory depression and cardiovascular disease in a placebo-controlled, double-blind crossover study design."	5.06	Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. ( Cooper, R; Gladson, M; Knos, G; Markwalter, H; Morris, R; Stoudemire, A; Sung, YF, 1990)
"The effect of labetalol on blood pressure, heart rate and the renin-angiotensin system was evaluated in 12 patients with severe essential hypertension (diastolic blood pressure greater than or equal to 120 mmHg, WHO: Phase I and II) who had been resistant to other therapeutic regimens."	3.66	Treatment of severe essential hypertension with labetalol: effect on active and inactive renin. ( Hauger-Klevene, JH, 1981)
"Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality."	2.61	Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019)
"Labetalol has been studied to a lesser extent and may have prolonged cardiovascular effects."	2.50	Beta-blocking agents during electroconvulsive therapy: a review. ( Birkenhäger, TK; Boere, E; Groenland, TH; van den Broek, WW, 2014)
" Carvedilol and labetalol are the best known examples of such combined alpha/beta-adrenoceptor antagonists, although their pharmacodynamic profile is a result of different receptor selectivity of their component stereoisomers, rather than combined alpha/beta-blocking activity in a single chemical entity."	2.38	An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. ( van Zwieten, PA, 1993)

Research

Studies (15)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Incidence of Same Symptom Stopping Bystolic as Previous Beta Blocker

Number of Participants With Intolerance of Bystolic, Measured by Side Effect(s) That Lead to Discontinuance of Bystolic by the Patient and/or the Physician

Number of Participants With Mild Symptoms

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (13.33)	18.7374
1990's	7 (46.67)	18.2507
2000's	2 (13.33)	29.6817
2010's	4 (26.67)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Reddy, S	1
Jim, B	1
Boere, E	1
Birkenhäger, TK	1
Groenland, TH	1
van den Broek, WW	1
Richards, JR	2
Lange, RA	2
Arnold, TC	1
Horowitz, BZ	1
Weber, MA	1
Pedersen, ME	1
Cockcroft, JR	1
Hauger-Klevene, JH	1
Stoudemire, A	3
van Zwieten, PA	1
Parr, MJ	1
Figiel, GS	1
McDonald, L	1
LaPlante, R	1
Rossi, GP	1
Zanin, L	1
Dessì-Fulgheri, P	1
Savastano, S	1
Cavazzana, A	1
Prayer-Galetti, T	1
Rappelli, A	1
Pessina, AC	1
Knos, G	1
Gladson, M	1
Markwalter, H	1
Sung, YF	1
Morris, R	1
Cooper, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984]	Phase 4	6 participants (Actual)	Interventional	2009-05-31	Terminated (stopped due to Lack of patient recruitment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Nebivolol	0

Intervention	Participants (Count of Participants)
Nebivolol	0

Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days

Article	Year
Hypertension and Pregnancy: Management and Future Risks. Advances in chronic kidney disease, 2019, Volume: 26, Issue:2 Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human	2019
Beta-blocking agents during electroconvulsive therapy: a review. British journal of anaesthesia, 2014, Volume: 113, Issue:1 Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Electroconvulsive Therapy; Humans; Labetalol;	2014
The role of the new beta-blockers in treating cardiovascular disease. American journal of hypertension, 2005, Volume: 18, Issue:12 Pt 2 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans	2005
The vasodilatory beta-blockers. Current hypertension reports, 2007, Volume: 9, Issue:4 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Antioxidants; Atenolol; Benzopyrans; Blood Pre	2007
An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs, 1993, Volume: 45, Issue:4 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiovascular Disea	1993

Article	Year
Labetalol and cardiovascular consequences of cocaine use. Trends in cardiovascular medicine, 2016, Volume: 26, Issue:2 Topics: Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Diseases; Cocaine; Cocaine-Related Diso	2016
Dual cocaine and methamphetamine cardiovascular toxicity: rapid resolution with labetalol. The American journal of emergency medicine, 2017, Volume: 35, Issue:3 Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Amphetamine-Related Disorders; Anti-Anxiet	2017
Treatment of severe essential hypertension with labetalol: effect on active and inactive renin. Pharmatherapeutica, 1981, Volume: 3, Issue:1 Topics: Adult; Blood Pressure; Cardiovascular Diseases; Ethanolamines; Female; Heart Rate; Humans; Hypertens	1981
Cardiovascular morbidity and ECT. The American journal of psychiatry, 1995, Volume: 152, Issue:11 Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Comorbidity; Depressive Disorder; Drug Therapy, Combi	1995
Cocaine dosage in rhinosurgery. Anaesthesia, 1993, Volume: 48, Issue:8 Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Cocaine; Humans; Labetalol; Propanolamines	1993
Cardiovascular complications of ECT. The American journal of psychiatry, 1994, Volume: 151, Issue:5 Topics: Cardiovascular Diseases; Depressive Disorder; Electroconvulsive Therapy; Humans; Hypertension; Labet	1994
Cardiovascular complications of ECT. The American journal of psychiatry, 1994, Volume: 151, Issue:5 Topics: Age Factors; Aged; Cardiovascular Diseases; Delirium; Depressive Disorder; Electroconvulsive Therapy	1994
A renin-secreting tumour with severe hypertension and cardiovascular disease: a diagnostic and therapeutic challenge. Clinical and experimental hypertension (New York, N.Y. : 1993), 1993, Volume: 15, Issue:2 Topics: Adult; Cardiovascular Diseases; Gene Expression; Humans; Hypertension, Renal; Kidney Neoplasms; Labe	1993
[Nifedipine, captopril and labetalol--overviews on the pattern of adverse effects]. Lakartidningen, 1985, Jul-10, Volume: 82, Issue:28-29 Topics: Captopril; Cardiovascular Diseases; Drug Eruptions; Ethanolamines; Gastrointestinal Diseases; Humans	1985

labetalol and Cardiovascular Diseases